Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - Purchase, NY – November 13, 20 ...

Clinical Trial Progress - CT1812 demonstrated a 95% slowing of cognitive decline on the ADAS-Cog11 scale and a 108% slowing on the MMSE scale in Alzheimer's disease patients with baseline p-tau217 levels below the median in the Phase 2 SHINE study [1][3] - The Phase 2 SHIMMER study investigating CT1812 in mild-to-moderate dementia with Lewy bodies (DLB) is on track to report topline results by the end of 2024 [1][2] - Enrollment continues in the Phase 2 START study for early Alzheimer's disease and the Phase 2 MAGNIFY study for geographic atrophy secondary to dry age-related macular degeneration [3] Financial Performance - Cash and cash equivalents as of September 30, 2024, were approximately $22.0 million, with $53.6 million in remaining grant funds from the NIA, sufficient to fund operations into Q2 2025 [4] - Research and development expenses decreased to $11.4 million in Q3 2024 from $11.7 million in Q3 2023, primarily due to lower costs with contract manufacturing organizations [5] - General and administrative expenses remained stable at $3.1 million in Q3 2024 compared to the same period in 2023 [6] - The company reported a net loss of $9.9 million, or $(0.25) per share, in Q3 2024, compared to a net loss of $6.7 million, or $(0.22) per share, in Q3 2023 [7] Strategic and Corporate Updates - The company plans to request an end-of-Phase 2 meeting with the FDA to review CT1812's safety, tolerability, and results from the SHINE study, aiming to align on a pivotal Phase 3 program design [2] - DLB, the second most common neurodegenerative disease, lacks disease-modifying treatments, and the SHIMMER study aims to provide safety and tolerability data for this under-studied population [2] - The company presented baseline characteristics of participants in the Phase 2 SHIMMER study at the CTAD conference, confirming enrollment of individuals with mild-to-moderate DLB [3]

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference ...

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc ...

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’ Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER’ trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will ...

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. Ms. Ricciardi also will host one-on-one investor meetings during which she will highligh ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, supports Lewy Body Dementia Awareness Month and the critical need for more attention, research, and treatments for people with dementia with Lewy bodies (DLB). DLB is the second most common form of progressive dementia, affecting approximately 1.4 million people in the U.S., with no approved treatments ...

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September. September 2024 Investor Conferences Event: Chardan Capital Markets Leadership Call Date/Time: September 5, 2024, at 11:00am ET Livestream: Individuals interested in attending the l ...

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Al ...

Financial Data and Key Metrics Changes - As of June 30, 2024, the company reported cash and cash equivalents of approximately $28.5 million and total grant funds remaining from the NIA of $57.3 million, indicating sufficient cash to fund operations into the second quarter of 2025 [18] - The net loss for the second quarter was $7 million or $0.18 per share, compared to a net loss of $4.7 million or $0.16 per share for the same period in 2023 [19] Business Line Data and Key Metrics Changes - Research and development expenses increased to $11.6 million for the second quarter of 2024 from $8.5 million in the same period of 2023, primarily due to higher costs associated with advancing clinical programs [18] - General and administrative expenses decreased to $3.1 million for the second quarter of 2024 from $3.3 million in the same period of 2023, attributed to lower professional services [19] Market Data and Key Metrics Changes - The SHINE trial showed a 39% slowing of cognitive decline in participants treated with CT1812 compared to placebo, indicating a significant potential in the Alzheimer's disease market [6][11] - The SHIMMER trial is expected to report top-line results by year-end, focusing on dementia with Lewy bodies, a market with an estimated 1.5 million affected individuals in the U.S. [13][14] Company Strategy and Development Direction - The company is focused on developing innovative drug candidates targeting age-related degenerative conditions of the CNS and retina, with ongoing Phase 2 trials for Alzheimer's disease and other conditions [4] - Future trials will be larger and longer to better assess the efficacy of CT1812, with a focus on safety and tolerability [32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the SHINE trial results, highlighting the consistent trends in cognitive improvement and the favorable safety profile of CT1812 [11][12] - The company plans to engage with leading neurologists to discuss next steps in CT1812 development, indicating a proactive approach to advancing their clinical programs [12] Other Important Information - The company has published multiple manuscripts and made presentations at medical conferences, supporting its development efforts and providing insights into the mechanisms of CT1812 [16] - The START trial is actively recruiting participants with early Alzheimer's disease, allowing for real-world evidence of CT1812's potential as both monotherapy and in combination with other treatments [15] Q&A Session Summary Question: Regarding the SHINE trial, how did the 100 mg dose affect A-beta levels? - The 100 mg dose did not significantly alter A-beta levels, while the 300 mg did, with expectations that longer trials may show more pronounced effects [20][22] Question: How does the company plan to extend its cash runway for later-stage trials? - The company is evaluating various options to extend its cash runway and will consider all available options as it designs the next stage of trials [23] Question: Is there potential synergy between CT1812 and GLP-1 receptor agonists for Alzheimer's treatment? - Management expressed interest in exploring potential synergies, noting that CT1812's mechanism could complement other therapies [24] Question: What are the key learnings from the SHINE trial for future studies? - Key learnings include the consistent trend in cognitive outcomes and the identification of a dose range that shows efficacy without significant adverse events [31][32] Question: How has the recent approval of Alzheimer's drugs affected trial enrollment? - The general awareness and interest in Alzheimer's treatments have positively impacted recruitment, although the patient populations for different trials are somewhat distinct [33]